Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.73 |
| ▸ | NPC1 | O15118 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15840528 | 0.97 | NPC1 (0.74) | RAB9ANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL15840802 | 0.83 | KMT2A (0.67) | RAB9ANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL15840620 | 0.82 | NPC1 (0.74) | RAB9ANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL15840531 | 0.81 | ALDH1A1 (0.91) | KMT2AMEN1ALDH1A1ALOX12LMNA | |
| SCHEMBL15840647 | 0.79 | ALDH1A1 (0.72) | KMT2AMEN1ALDH1A1ALOX12LMNA | |
| SCHEMBL15840795 | 0.79 | KMT2A (0.81) | RAB9ANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL15840597 | 0.78 | ALDH1A1 (1.00) | KMT2AMEN1ALDH1A1ALOX12LMNA | |
| SCHEMBL15840546 | 0.78 | ALDH1A1 (0.78) | RAB9ANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL15840642 | 0.78 | KMT2A (0.71) | RAB9ANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL13454635 | 0.77 | ALDH1A1 (0.69) | RAB9ANPC1KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | RAB9A 2629/4885NPC1 3164/4885KMT2A 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.